JP2016529235A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529235A5
JP2016529235A5 JP2016526992A JP2016526992A JP2016529235A5 JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5 JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5
Authority
JP
Japan
Prior art keywords
optionally
amino
group
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529235A (ja
JP6653253B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/046203 external-priority patent/WO2015009545A1/en
Publication of JP2016529235A publication Critical patent/JP2016529235A/ja
Publication of JP2016529235A5 publication Critical patent/JP2016529235A5/ja
Application granted granted Critical
Publication of JP6653253B2 publication Critical patent/JP6653253B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526992A 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのn−尿素置換アミノ酸の誘導体 Expired - Fee Related JP6653253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846787P 2013-07-16 2013-07-16
US61/846,787 2013-07-16
PCT/US2014/046203 WO2015009545A1 (en) 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

Publications (3)

Publication Number Publication Date
JP2016529235A JP2016529235A (ja) 2016-09-23
JP2016529235A5 true JP2016529235A5 (enExample) 2017-08-17
JP6653253B2 JP6653253B2 (ja) 2020-02-26

Family

ID=51230227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526992A Expired - Fee Related JP6653253B2 (ja) 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのn−尿素置換アミノ酸の誘導体

Country Status (11)

Country Link
US (1) US9428549B2 (enExample)
EP (1) EP3022174B1 (enExample)
JP (1) JP6653253B2 (enExample)
KR (1) KR102313757B1 (enExample)
CN (1) CN105377814B (enExample)
AU (1) AU2014290618B2 (enExample)
CA (1) CA2917811C (enExample)
DK (1) DK3022174T3 (enExample)
ES (1) ES2708571T3 (enExample)
RU (1) RU2696581C2 (enExample)
WO (1) WO2015009545A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5982001B2 (ja) 2011-10-26 2016-08-31 アラーガン、インコーポレイテッドAllergan,Incorporated ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体
WO2014138046A1 (en) 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
JP6496728B2 (ja) 2013-11-21 2019-04-03 アラーガン、インコーポレイテッドAllergan,Incorporated ホルミルペプチド受容体の調節因子としてのカルバミン酸フェニル誘導体
NZ720508A (en) 2013-11-28 2019-03-29 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
BR112016027133A8 (pt) 2014-05-21 2021-06-29 Allergan Inc derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
EA201792382A1 (ru) 2015-05-27 2018-04-30 Киорин Фармасютикал Ко., Лтд. Производное мочевины или его фармакологически приемлемая соль
JP6900365B2 (ja) * 2015-08-05 2021-07-07 アラーガン、インコーポレイテッドAllergan,Incorporated ホルミルペプチド受容体1(fpr1)選択的アゴニストとしてのフェニル尿素類似体
AU2019232704B2 (en) 2018-03-05 2024-03-21 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US5284828A (en) * 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) * 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
JP2968842B2 (ja) * 1994-02-09 1999-11-02 塩野義製薬株式会社 カルバモイルメチルウレア誘導体
RU2134684C1 (ru) * 1994-02-09 1999-08-20 Сионоги Энд Ко., Лтд. Производные карбамоилмочевины и фармацевтическая композиция
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU4572999A (en) * 1998-06-18 2000-01-05 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
AU2003214249A1 (en) * 2002-04-03 2003-10-13 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
KR20060130064A (ko) * 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, fprl1의 용도
NZ597122A (en) * 2009-05-18 2013-06-28 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists
CA2819457A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
JP5982001B2 (ja) * 2011-10-26 2016-08-31 アラーガン、インコーポレイテッドAllergan,Incorporated ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのn−尿素置換アミノ酸のアミド誘導体
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8735622B2 (en) * 2011-11-30 2014-05-27 The Regents Of The University Of Colorado, A Body Corporate Histone demethylase inhibitors and methods for using the same
CA2898301C (en) * 2013-03-06 2021-11-16 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
WO2014138046A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Similar Documents

Publication Publication Date Title
JP2016529235A5 (enExample)
JP2017537940A5 (enExample)
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
JP2016530310A5 (enExample)
JP2019514874A5 (enExample)
PH12020551616A1 (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2016536364A5 (enExample)
JP2016536363A5 (enExample)
JP2015537020A5 (enExample)
JP2014511892A5 (enExample)
JP2016503797A5 (enExample)
JP2017523225A5 (enExample)
JP2014502979A5 (enExample)
RU2012125372A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2017517538A5 (enExample)
JP2012513416A5 (enExample)
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
JP2015508092A5 (enExample)
JP2016531126A5 (enExample)
JP2015535847A5 (enExample)
JP2019535723A5 (enExample)
JP2018048143A5 (enExample)
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2016528273A5 (enExample)